This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Soriatane

GlaxoSmithKline plc

Drug Names(s): Acitretin

Description: Soriatane is an oral retinoid, which is related to vitamin A. Soriatane is believed to activate Retinoic acid receptors (RARs). It normalizes the growth cycle of skin cells by reducing cellular proliferation and stimulating differentiation. It also decreases inflammation in the epidermis and dermis by interfering with various cytokines. However, in contrast to other systemic antipsoriatic drugs, acitretin is neither cytotoxic nor immunosuppressive.

Deal Structure: On March 4, 2004 Connetics Corporation acquired exclusive rights to Roche's Soriatane. The brand was purchased for $123 million in cash.

In December 2006, Connetics was aquired by Stiefel Laboratories.

In April 2009, GlaxoSmithKline and Stiefel Laboratories announced that they have signed an agreement under which GSK will acquire Stiefel in a deal valued at up to $3.6 billion. GSK's existing prescription dermatological products will be combined with Stiefel's and the new specialist global business will operate under the Stiefel identity within the GSK Group. The acquisition was completed in July 2009.


Soriatane News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug